Skip to main content
. 2016 Apr 11;7(22):32532–32542. doi: 10.18632/oncotarget.8687

Figure 2. Leukemic stem cell (LSC) differentiation during treatment with RG7356.

Figure 2

LSC differentiation during treatment with RG7356 (patient 3015, 600 mg, twice weekly dose regimen, on treatment for 26 cycles). LSC differentiation is shown by reduction of percentage of CD34+ blasts and percentage increase of CD34/CD38+ blasts in the bone marrow. Hematologic improvement (HI) is shown by absolute neutrophil count (ANC) increase (green line).